Cetuximab

被引：137

作者：

Graham, J ^{[1
]}

Muhsin, M ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] Decis Resources Int, London WC1B 4HQ, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2004年 / 3卷 / 07期

关键词：

D O I：

10.1038/nrd1445

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials.

引用

页码：549 / 550

页数：2

共 9 条

[1]

Baselga J, 2001, EUR J CANCER, V37, pS16

[2]

BURTNESS BA, 2002, P AN M AM SOC CLIN, V21, pA226

[3] Cytotoxic and molecular-targeted therapies of head and neck tumors [J].